Medical
-
A study published online in CHEST on June 25, 2015 finds that discontinuing inhaled corticosteroids for COPD patients reduced the risk of pneumonia by 37%, with the greatest reduction in risk associated with stopping inhaled… Read more . . .
-
OptiNose has announced positive results from the 24-week Phase 3 trial of OPN-375, an intranasal fluticasone product for the treatment for nasal polyps based on the company’s Bi-Directional Breath-Powered delivery system. The study showed statistically… Read more . . .
-
A study published online June 11 2015 in the American Journal of Respiratory and Critical Care Medicine showed that asthma patients over 30 years of age who were using inhaled corticosteroids experienced a greater proportion… Read more . . .
-
AmpliPhi BioSciences has announced that a study performed in conjunction with the Royal Brompton Hospital and Imperial College, UK showed that a variety of bacteriophages remain viable against P. aeruginosa after nebulization. Three different commercially… Read more . . .
-
Novartis has announced positive results from several Phase 3 studies of NVA237 glycopyrronium bromide and QVA149 indacaterol/glycopyrronium bromide, both delivered by the Breezhaler DPI for the treatment of COPD. NVA237 is marketed as Seebri Breezhaler… Read more . . .
-
Sunovion Pharmaceuticals has presented results from three studies of Brovana arformoterol tartrate inhalation solution for the treatment of COPD at ATS 2015. According to Sunovion, the studies show that Brovana produces clinically significant improvement in… Read more . . .
-
Boehringer Ingelheim Pharmaceuticals has presented new data analyses from two Phase 3 studies of its tiotropium/olodaterol Respimat SMI for the treatment of COPD at ATS 2015. The two efficacy and safety studies (NCT01431274 and NCT01431287),… Read more . . .
-
Discovery Laboratories has announced that data from a Phase 2a clinical trial of Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome (RDS) in premature infants show that the novel delivery technology performed… Read more . . .
-
In a note accompanying a set of articles on the impact of the FDA’s ban on the use of CFC propellants in metered dose inhalers and the transition to HFA inhalers, published online on May… Read more . . .
-
Adamis Pharmaceuticals has announced that a clinical study comparing its APC-2000 albuterol MDI with GSK’s Ventolin Evohaler MDI met its primary endpoint, showing equivalence in change from baseline of FEV1 for both doses tested (100… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland